MoonLake Immunotherapeutics (MLTX) Profit After Tax (2021 - 2026)
MoonLake Immunotherapeutics' (MLTX) quarterly Profit After Tax came in at -$70.0 million in Q1 2026, down 75.22% year-on-year from -$282.4 million in Q1 2025, and little changed quarter-over-quarter from -$69.9 million in Q4 2025.
MoonLake Immunotherapeutics (MLTX) Profit After Tax (2021 - 2026) Analysis & Trends
MoonLake Immunotherapeutics' Profit After Tax history runs 6 years deep, the most recent figure standing at -$70.0 million for Q1 2026.
- On a quarterly basis, Profit After Tax fell 75.22% year-over-year to -$70.0 million in Q1 2026; TTM through Mar 2026 was -$265.9 million, a 84.34% decrease from a year earlier, with the FY2025 full-year figure at -$234.8 million, down 101.75% from the prior year.
- Profit After Tax steadied at -$70.0 million in Q1 2026 per MLTX's latest filing, from -$69.9 million in the prior quarter.
- Across five years, Profit After Tax topped out at -$6.6 million in Q3 2023 and bottomed at -$70.0 million in Q1 2026.
- The 5-year median for Profit After Tax is -$17.4 million (2022), against an average of -$31.1 million.
- Biggest YoY gain for Profit After Tax was 69.4% in 2022; the steepest drop was 4415.6% in 2022.
- Year by year, Profit After Tax stood at -$16.5 million in 2022, then surged by 48.9% to -$8.4 million in 2023, then sank by 416.24% to -$43.4 million in 2024, then sank by 60.93% to -$69.9 million in 2025, then declined by 0.11% to -$70.0 million in 2026.
- Per Business Quant, the three latest MLTX Profit After Tax figures stand at -$70.0 million (Q1 2026), -$69.9 million (Q4 2025), and -$70.0 million (Q3 2025).
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | PAT (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | -36.84 Mn |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 227.36 Mn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 1.03 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | -65.60 Mn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | -26.94 Mn |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | 362.00 Mn |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | -453.82 Mn |
| 10 | MoonLake Immunotherapeutics | 1.38 Bn | 1.02 Bn | - | -69.99 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -69.99 Mn |
| Dec 31, 2025 | -69.91 Mn |
| Sep 30, 2025 | -69.97 Mn |
| Jun 30, 2025 | -56.05 Mn |
| Mar 31, 2025 | -39.94 Mn |
| Dec 31, 2024 | -43.44 Mn |
| Sep 30, 2024 | -36.11 Mn |
| Jun 30, 2024 | -24.76 Mn |
| Mar 31, 2024 | -13.98 Mn |
| Dec 31, 2023 | -8.42 Mn |
| Sep 30, 2023 | -6.59 Mn |
| Jun 30, 2023 | -12.35 Mn |
| Mar 31, 2023 | -12.22 Mn |
| Dec 31, 2022 | -16.47 Mn |
| Sep 30, 2022 | -14.74 Mn |
| Jun 30, 2022 | -17.42 Mn |
| Mar 31, 2022 | -15.88 Mn |
| Dec 31, 2021 | -53.81 Mn |
| Sep 30, 2021 | -6.29 Mn |
| Jun 30, 2021 | -32.69 Mn |